ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Late-Breaking 2021"

  • Abstract Number: L02 • ACR Convergence 2021

    COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases

    Ines Colmegna1, Mariana Useche1, Emmanouil Rampakakis2, Nathalie Amiable3, Emmanuelle Rollet-Labelle3, Louis Bessette4, Jo-Anne Costa4, Marc Dionne4, Mary-Ann Fitzcharles2, Elizabeth Hazel2, Deirdre McCormack2, Laetitia Michou4, Pantelis Panopalis2, Marc-Andre Langlois5, Sasha Bernatsky6 and Paul R. Fortin7, 1The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada, 3Centre de Recherche du CHU de Quebec, Quebec, Canada, 4Universite Laval, Quebec, QC, Canada, 5University of Ottawa, Ottawa, ON, Canada, 6McGill University, Montreal, QC, Canada, 7CHU de Quebec - Universite Laval, Quebec, Canada

    Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
  • Abstract Number: L18 • ACR Convergence 2021

    Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study

    Satveer K Mahil1, Katie Bechman2, Antony Raharja1, Clara Domingo-Vila3, David Baudry1, Matt Brown2, Andrew Cope2, Tejus Dasandi1, Hataf Khan4, Thomas Lechmere4, Michael Malim4, Freya Meynell1, Emily Pollock3, Kamila Sychowska3, Jonathan Barker1, Sam Norton5, James Galloway2, Katie Doores4, Timothy Tree3 and Catherine Smith1, 1St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, 2Centre for Rheumatic Diseases, King's College London, London, 3Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, 4Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, 5Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London

    Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
  • Abstract Number: L03 • ACR Convergence 2021

    COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine

    Kyriakos Kirou and Jeffrey Zhang-Sun, Hospital for Special Surgery, New York, NY

    Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate…
  • Abstract Number: L19 • ACR Convergence 2021

    Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial

    Nils Venhoff1, Wolfgang Schmidt2, Raoul Bergner3, Jürgen Rech4, Leonore Unger5, Hans-Peter Tony6, Meryl Mendelson7, Christian Sieder8, Meron Maricos8 and Jens Thiel9, 1Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, 2Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, 3Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 5Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, 6Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma GmbH, Nuremberg, Germany, 9Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
  • Abstract Number: L04 • ACR Convergence 2021

    SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry

    Jean Liew1, milena Gianfrancesco2, Carly Harrison3, zara Izadi2, Stephanie Rush2, Lindsay Jacobsohn2, Clairissa Ja2, Saskia Lawson-Tovey4, Kimme Hyrich5, Laure Gossec6, Anja Strangfeld7, Loreto Carmona8, Martin Schaefer7, ELSA MATEUS9, Samar Al Emadi10, Claire Cook11, Fatemah Abutiban12, Dfiza Dey13, Emily Kowalski14, Marco Martinez-Martinez15, Naomi Patel11, Evelyn Salido16, Jeffrey Sparks17, leanna Wise18, Suleman Bhana19, Wendy Costello20, Rebecca Grainger21, Jonathan Hausmann22, Emily Sirotich23, Paul Sufka24, Zachary Wallace25, Pedro Machado26, Philip Robinson27 and Jinoos Yazdany2, 1Boston University School of Medicine, Boston, MA, 2University of California San Francisco, San Francisco, CA, 3Lupus Chat, New York, NY, 4Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 6INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France, Paris, France, 7German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany, 8Instituto de Salud Musculoesquelética, Madrid, Spain, 9EULAR, Lisboa, Portugal, 10Hamad Medical Corporation, Doha, Qatar, 11Massachusetts General Hospital, Boston, MA, 12Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, KUWAIT, Kuwait, 13Rheumatology Unit , Department of Medicine and Therapeutics, University of Ghana Medical School, Korle Bu Teaching Hospital, Accra, Ghana, 14Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 15Instituto Mexicano del Seguro Social, San Luis Potosí, Mexico, 16University of the Philippines Manila, Manila, Philippines, 17Brigham and Women's Hospital, Boston, MA, 18University of Southern California, Los Angeles, CA, 19Pfizer, Montvale, NJ, 20Irish Children's Arthritis Network (iCAN), Bansha, Ireland, 21University of Otago, Wellington, New Zealand, 22Boston Childrens Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 23McMaster University, Hamilton, ON, Canada, 24HealthPartners, Eagan, MN, 25Massachusetts General Hospital, Harvard Medical School, Boston, MA, 26Centre for Rheumatology & Department of Neuromuscular Diseases, University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom, 27University of Queensland School of Clinical Medicine, Herston, Queensland; Department of Rheumatology, Royal Brisbane and Women’s Hospital, Metro North Hospital and Health Service, Queensland, Australia., Brisbane, Australia

    Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical characteristics of…
  • Abstract Number: L20 • ACR Convergence 2021

    Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)

    Fabrizio De Benedetti1, Alexei Grom2, Paul Brogan3, Claudia Bracaglia1, Manuela Pardeo1, Giulia Marucci1, Despina Eleftheriou3, Charalampia Papadopoulou3, Pierre Quartier4, Jordi Antón5, Rikke Frederiksen6, Veronica Asnaghi6 and Cristina De Min6, 1Bambino Gesù Children's Hospital IRCCS, Rome, Italy, 2Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, 3UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 4Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 5Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, 6Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology